RADAR on Specialty Pharmacy

Amid COVID-Spurred Shifts in Home Infusion, Model May Morph

With numerous hospitals focused on the COVID-19 pandemic and many areas under stay-at-home mandates, home infusion is more important than ever. Changes within the industry already have been seen, and the current sit...

Biosimilars May Be Impacting Payers’ Medical Benefit Spend

Over the past decade, commercial per-member per-month (PMPM) drug spend under the medical benefit has almost doubled, according to Magellan Rx Management, a division of Magellan Health, Inc. The company just rele...

Some Payers Say They May Allow Off-Label Use of Jelmyto

On April 15, the FDA approved the first drug for patients with low-grade upper tract urothelial cancer, UroGen Pharma Ltd.’s Jelmyto (mitomycin). It offers patients a nonsurgical option for a condition that often ...

Prime Studies Show High Costs Among Asthma, HAE Biologics

Prime Therapeutics LLC recently released the results of two studies focused on two classes of high-cost biologics, asthma and hereditary angioedema (HAE). Both conditions have seen new therapies recently and may be ...

SDMC Pharmacist, Integrated Data Can Produce Savings

High cost is only one characteristic of specialty drugs that makes managing them so important. They fall under both the pharmacy and medical benefits, they have complicated treatment regimens, and they have fraud, w...

New FDA Specialty Approvals

✦ April 8: The FDA granted an additional approval to Pfizer Inc. subsidiary Array BioPharma Inc.’s Braftovi (encorafenib) in combination with Lilly USA, LLC’s Erbitux (cetuximab) for the treatment of adults wi...

News Briefs

✦ Ontruzant (trastuzumab-dttb) launched on April 15. Merck & Co., Inc. will commercialize the Herceptin (trastuzumab) biosimilar in the U.S. per a deal with Samsung Bioepis Co., Ltd. Ontruzant is available in ...

Specialty Pharmacies Have Many Roles to Play During Outbreak

As the COVID-19 pandemic continues its assault on the globe and the U.S. passes 12,000 deaths from it, all eyes are on the health care industry. While the public looks to pharma manufacturers for potential treatment...

Manufacturers Can Assist Other Stakeholders in COVID Battle

As the new coronavirus continues its spread, pharma companies are finding themselves facing a spate of challenges. And although they’ll need to find ways to counter those setbacks, they also can help address issue...

Sarclisa Is Likely to Be Managed At Parity With Similar Drugs

On March 2, the FDA approved Sanofi’s Sarclisa (isatuximab-irfc) for the treatment of multiple myeloma, a hematologic malignancy. The move added another therapy to a class full of products, both indicated for the ...